Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark) was specifically developed for use in hemophilia A and hemophilia B patients with corresponding factor inhibitors [1]. The Food and Drug Administration (FDA) approved rFVIIa in the United States in 1999 for management of bleeding episodes in patients with congenital hemophilia A or B with inhibitors (auto-antibodies to coagulation factors VIII and IX). The label was subsequently expanded to include patients with acquired hemophilia, congenital factor VII deficiencies and inherited platelet disorders.